Subcutaneous Pharmacokinetics of Belatacept

Completed · Phase 1 · Has a placebo group

Conditions studied: Transplantation

In brief

Pharmacokinetics, Bioavailability, Safety and Immunogenicity of Single Doses of Belatacept Administered Subcutaneously to Healthy Subjects

Key facts

Study ID

NCT00569803

Run by

Bristol-Myers Squibb

People needed

153

Starts

2007-12-01

Expected to finish

2008-08-01

Last updated by the study team

2016-09-22

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Men and women ages 18 to 65 years old
• Subjects must weigh less than or equal to 100 kg

You may not qualify if…

• Inability to tolerate injections or IV infusions
• autoimmune disorders
• TB
• herpes
• HCV
• HBV
• HIV
• bacterial or viral infection
• history of cancer

Where it is running

• Ppd Development — Austin, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.